Corporate Profile

Cordlife Group Limited at a glance

Established in May 2001, Cordlife Group Limited ("Cordlife", together with its subsidiaries, the "Group") is a leading company dedicated to safeguarding the well-being of mother and child. The Group is listed on the Mainboard of the Singapore Exchange since 2012 and is a pioneer in private cord blood banking in Asia.

Cordlife owns the largest network of cord blood banks in Asia with full stem cell banking facilities in six key markets, namely Singapore, Hong Kong, Indonesia, India, Malaysia and the Philippines. In Singapore, Hong Kong, the Philippines and Indonesia, Cordlife operates the largest private cord blood banks and it is amongst the top three market leaders in India and Malaysia. In January 2018, Cordlife became the market leader in Hong Kong with the acquisition of the largest private cord blood bank, Healthbaby Biotech (Hong Kong) Co., Limited. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife holds an indirect stake in Thailand's largest private cord blood bank, Thai Stemlife. Cordlife has also established its presence in Myanmar, Vietnam, Macau, Brunei and Bangladesh.

Beyond cord blood, cord lining and cord tissue banking, Cordlife offers a comprehensive suite of diagnostics services for the family including non-invasive prenatal testing, paediatric vision screening, newborn metabolic screening and family genetic screening services.

Quality and customer focus are amongst some of the cornerstones of Cordlife. All of the Group's facilities are accredited by AABB (formerly known as American Association of Blood Banks), the organisation behind the world's gold standard for cord blood banking. In addition, Cordlife Singapore and Healthbaby Hong Kong are also two of the four private cord blood banks in Asia, and eight in the world, to be accredited by both AABB and Foundation for the Accreditation of Cellular Therapy ("FACT"), another world-class accreditation body for cord blood banks globally.

In the area of clinical diagnostics, Cordlife India, Cordlife Hong Kong and Healthbaby Hong Kong are accredited by the College of American Pathologists ("CAP"). This makes Healthbaby Hong Kong the only private cord blood bank in the world to be accredited by three international standard-setting bodies and Cordlife India one of the only two medical laboratories in West Bengal to be holding accreditations from National Accreditation Board for Testing and Calibration Laboratories ("NABL") and CAP. These quality achievements underpin the Group's commitment to providing reliable healthcare solutions through innovation and technological advancement.

About Cordlife India

Cordlife India is a fully owned subsidiary of Cordlife Group Limited. The Indian Laboratory is AABB accredited and operates the most advanced umbilical cord and cord blood processing, testing and cryopreservation facility in the country, with a storage capacity of 200,000 cord blood units scalable by another few lakh units.

The state-of-the-art laboratory is equipped with the latest and the most modern equipment and has recently upgraded from the automated Sepax®2 to the FDA approved AXP®II. Its MNC (Mono Nuclear Cells) and CD34+ recovery rate is higher.^[1]

It maintains a clean-room infrastructure to ensure that stem cells are processed under the most sterile conditions. Located within a natural calamity proof building, the facility is also built with continuous power backup and round-the-clock surveillance system. Cordlife operates in more than 210 cities across India, making it one of the largest stem cell banking companies locally.

References:
1. Christy Kim et al. Meta-analysis of the AXP® and SEPAX® automated cord blood processing systems. CESCA Therapeutics White Paper; 2015.